A pharmaceutical agent for treating an amyloid disease in a patient, wherein the pharmaceutical agent comprises glucose pentasulfate or a pharmaceutically acceptable salt thereof. The agent is directed to amyloid diseases in general and to type II diabetes in particular. Methods of treating an amyloid disease in a patient by administering therapeutically effective amounts of glucose pentasulfate are also presented.